| Hormonal Regulation and Hypertension | Lifetime | 2 | US 2 | 99.94 |
| Blood Pressure and Hypertension Studies | Lifetime | 4 | US 2 | 99.96 |
| Chronic Kidney Disease and Diabetes | Lifetime | 6 | US 4 | 99.90 |
| Diabetes Treatment and Management | Lifetime | 11 | US 6 | 99.90 |
| Pharmacology and Obesity Treatment | Lifetime | 6 | US 3 | 99.82 |
| Cardiovascular Syncope and Autonomic Disorders | Lifetime | 11 | US 6 | 99.68 |
| Potassium and Related Disorders | Lifetime | 4 | US 4 | 99.86 |
| Electrolyte and hormonal disorders | Lifetime | 13 | US 7 | 99.68 |
| Heart Rate Variability and Autonomic Control | Lifetime | 42 | US 19 | 99.71 |
| Sodium Intake and Health | Lifetime | 6 | US 4 | 99.79 |
| Renin-Angiotensin System Studies | Lifetime | 13 | US 6 | 99.64 |
| Dialysis and Renal Disease Management | Lifetime | 43 | US 20 | 99.66 |
| Cardiovascular Health and Disease Prevention | Lifetime | 81 | US 38 | 99.44 |
| Diet and metabolism studies | Lifetime | 245 | US 106 | 99.45 |
| Heart Failure Treatment and Management | Lifetime | 132 | US 67 | 99.47 |
| Renal and Vascular Pathologies | Lifetime | 106 | US 70 | 99.10 |
| Diabetes Management and Research | Lifetime | 536 | US 244 | 98.20 |
| Renal function and acid-base balance | Lifetime | 214 | US 116 | 97.48 |
| Hemodynamic Monitoring and Therapy | Lifetime | 423 | US 163 | 97.64 |
| Pancreatic function and diabetes | Lifetime | 907 | US 380 | 97.73 |
| Diabetes, Cardiovascular Risks, and Lipoproteins | Lifetime | 593 | US 248 | 98.12 |
| Apelin-related biomedical research | Lifetime | 211 | US 73 | 94.16 |
| Eicosanoids and Hypertension Pharmacology | Lifetime | 814 | US 399 | 95.75 |
| Acute Kidney Injury Research | Lifetime | 803 | US 303 | 93.33 |
| Heart rate and cardiovascular health | Lifetime | 126 | US 44 | 91.53 |
| Erythropoietin and Anemia Treatment | Lifetime | 935 | US 363 | 88.84 |
| Magnesium in Health and Disease | Lifetime | 634 | US 225 | 86.88 |
| Blood Pressure and Hypertension Studies | 2021-2025 | 2 | US 1 | 99.85 |
| Hormonal Regulation and Hypertension | 2021-2025 | 2 | US 2 | 99.92 |
| Electrolyte and hormonal disorders | 2021-2025 | 3 | US 2 | 99.16 |
| Diabetes Treatment and Management | 2021-2025 | 22 | US 13 | 99.76 |
| Sodium Intake and Health | 2021-2025 | 8 | US 4 | 98.88 |
| Diet and metabolism studies | 2021-2025 | 106 | US 34 | 98.55 |
| Apelin-related biomedical research | 2021-2025 | 5 | US 1 | 94.67 |
| Chronic Kidney Disease and Diabetes | 2021-2025 | 76 | US 29 | 97.87 |
| Dialysis and Renal Disease Management | 2021-2025 | 165 | US 37 | 96.44 |
| Cardiovascular Function and Risk Factors | 2021-2025 | 499 | US 187 | 96.62 |
| Diabetes Management and Research | 2021-2025 | 324 | US 142 | 96.12 |
| Pancreatic function and diabetes | 2021-2025 | 406 | US 155 | 93.24 |
| Potassium and Related Disorders | 2021-2025 | 64 | US 30 | 94.54 |
| Cardiovascular, Neuropeptides, and Oxidative Stress Research | 2021-2025 | 38 | US 5 | 88.97 |
| Heart Failure Treatment and Management | 2021-2025 | 690 | US 214 | 92.05 |
| Metabolism, Diabetes, and Cancer | 2021-2025 | 642 | US 162 | 84.49 |
| Ion Transport and Channel Regulation | 2021-2025 | 123 | US 39 | 84.57 |
| Renin-Angiotensin System Studies | 2021-2025 | 74 | US 28 | 84.19 |
| Bipolar Disorder and Treatment | 2021-2025 | 594 | US 117 | 85.57 |
| Adrenal Hormones and Disorders | 2021-2025 | 569 | US 82 | 73.42 |
| Pharmacology and Obesity Treatment | 2021-2025 | 601 | US 232 | 68.69 |
| Hyperglycemia and glycemic control in critically ill and hospitalized patients | 2021-2025 | 618 | US 223 | 68.60 |
| Eicosanoids and Hypertension Pharmacology | 2021-2025 | 495 | US 142 | 67.71 |
| Cardiovascular Syncope and Autonomic Disorders | 2021-2025 | 950 | US 300 | 64.29 |
| Renal function and acid-base balance | 2021-2025 | 735 | US 200 | 54.48 |
